Back

SGLT2i downregulate the activin/inhibin and miR-1306-5p signaling pathways in patients with HFrEF and associated pulmonary hypertension: a prospective intervention study

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Pulmonary arterial hypertension: general (3) Treatment ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Mattia Alberti

University Hospital of Pisa, Pisa (Italy)

6 More presentations in this session

Presentation thumbnail
Insulin resistance indices are associated with the presence and outcomes of pulmonary hypertension due to left heart failure
Doctor R. Quan (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Left atrial V-wave as a potential new pathophysiological trigger of pulmonary hypertension
Doctor F. Bauer (Le Kremlin-Bicetre, FR)
Abstract Slides Video
Presentation thumbnail
Early CMR-derived markers of right ventricular involvement in combined post- and pre-capillary pulmonary hypertension
Doctor C. Perez Garcia (Madrid, ES)
Abstract Slides Video
Presentation thumbnail
Mapping right ventricular adaptation in pulmonary arterial hypertension: insights from a six-phenotype model
Doctor A. Lescano (Gran Buenos Aires, AR)
Abstract Slides Video
Presentation thumbnail
The albumin-bilirubin score predicts severity and long-term outcomes in patients with chronic thromboembolic pulmonary hypertension
Doctor D. Sirma (Istanbul, TR)
Abstract Slides Video

Access the full session

Session thumbnail
Pulmonary arterial hypertension: general (3)

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Unravel novel therapeutic targets in heart failure and associated pulmonary hypertension
thumbnail
Congress Presentation
Combined ARNI and SGLT2i impacts on peak tricuspid regurgitant velocity and echocardiographic probability of pulmonary hypertension
thumbnail
Congress Presentation
Dapagliflozin effect on cardiopulmonary function, reverse cardiac remodelling and biomarkers in a cohort of HFrEF patients

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources